Catalyst Brief

← Calendar

ReadoutIn window

Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair — ETOPOSIDE - Usual

Phase 3 primary completion: Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms.

Date
Nov 2026
Type
Readout
Indication
Small Cell Lung Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.